Efficacy of the DigniCap System in preventing chemotherapy‐induced alopecia in breast cancer patients is not related to patient characteristics or side effects of the device
| Autor: | Alfredo Berruti, Susanna Bianchi, Mara Ardine, Antonella Turla, Alberto Dalla Volta, Deborah Cosentini, Carla Fornaro, Rebecca Pedersini, Paolo Carlo Motta, Edda Simoncini, Filippo Rodella, Vito Amoroso, Elisa Conti, Maria Gelmi, Pierluigi di Mauro, Michela Pierini, Lucia Vassalli |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
medicine.medical_specialty chemotherapy-induced alopecia Antineoplastic Agents Breast Neoplasms scalp cooling 03 medical and health sciences breast cancer 0302 clinical medicine Breast cancer nursing Hypothermia Induced Trastuzumab Internal medicine Humans Medicine Prospective Studies oncology 030212 general & internal medicine Prospective cohort study General Nursing Aged Scalp integumentary system 030504 nursing business.industry Alopecia Middle Aged medicine.disease Chemotherapy regimen Regimen Treatment Outcome medicine.anatomical_structure Hair loss Tolerability Patient Satisfaction Quality of Life Female 0305 other medical science business medicine.drug |
| Zdroj: | International Journal of Nursing Practice. 27 |
| ISSN: | 1440-172X 1322-7114 |
| DOI: | 10.1111/ijn.12888 |
| Popis: | Background The DigniCap System is an effective scalp cooling device for the prevention of chemotherapy-induced alopecia in early breast cancer patients. Aim This prospective study was designed to confirm the efficacy and tolerability of the device, to explore potential factors associated with its efficacy and to collect data on patient perceptions and satisfaction. Methods Between January 2016 and June 2018, 163 early breast cancer patients eligible for adjuvant chemotherapy were enrolled. Hair loss was assessed using the Dean scale, where a score of 0-2 (hair loss ≤50%) was defined as successful. Results Hair preservation was successful in 57% of patients in the overall series. The proportion was even higher (81%) in the patient subgroup treated with a paclitaxel and trastuzumab regimen. Side effects (feeling cold, headache, head heaviness, scalp and cervical pain) were mild to moderate and did not correlate with the rate of hair loss. Lifestyle, anthropometric factors and hair characteristics failed to be associated with device efficacy. Conclusions The DigniCap System was well tolerated and found to be effective in preventing alopecia in early breast cancer patients. Our study failed to identify factors other than type of chemotherapy regimen associated with hair preservation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text